Synthetic Applications of Haloalkanes:
-
Alcohol synthesis via SN2: Primary haloalkanes + NaOH (aqueous) → primary alcohols with Walden inversion. Example: + NaOH (DMSO) → .
-
Nitrile synthesis (chain extension): R-X + NaCN (DMSO) → R-CN (nitrile, adds one carbon). Hydrolysis → carboxylic acid. Key for increasing chain length.
-
Ether synthesis (Williamson synthesis): R-X + R'O^{-}$$Na^{+} → R-O-R' + NaX. SN2 mechanism; must use 1° alkyl halide to avoid E2 from the alkoxide base.
-
Grignard reagents from haloalkanes: R-X + Mg (dry ether) → R-MgX. Used to form C-C bonds with aldehydes (→ 2° alcohol), ketones (→ 3° alcohol), (→ carboxylic acid), formaldehyde (→ 1° alcohol). Chain extension reactions are fundamental in synthesis planning.
-
Alkene synthesis via elimination: R-X + KOH/ethanol (hot) → alkene. E2 with Saytzeff selectivity. Anti-Markovnikov addition of HBr (peroxide) to alkene, then E2, allows isomerization of halide position.
-
Halogen exchange (interconversion of haloalkanes):
- Finkelstein: RCl → RI (NaI/acetone). When you need iodoalkane from chloroalkane.
- Swarts: RBr → RF (AgF). When you need fluoroalkane (cannot make by direct fluorination).
- RI is most reactive and preferred for SN2 reactions due to being the best leaving group.
Industrial Applications:
-
Phenol production (Dow process): Chlorobenzene + NaOH (623 K, 300 atm) → phenol. Phenol is a major industrial chemical for making phenolic resins, bisphenol-A (plastics), aspirin precursors. The Dow process was the first industrial route to phenol.
-
Refrigerants (CFCs → HFCs): Freon-12 () was used as a refrigerant but depletes ozone. Replaced by HFCs (hydrofluorocarbons, no Cl) after Montreal Protocol 1987. C-F bonds in HFCs are stable to UV and do not release ozone-depleting Cl• radicals.
-
Solvents: Chlorinated solvents (, , ) are used in industry as non-flammable, polar solvents. However, they are potential environmental contaminants and health hazards ( is hepatotoxic; → phosgene on oxidation).
-
Pharmaceutical applications: C-F bonds are introduced into drug molecules to improve metabolic stability (C-F bond resists oxidation by cytochrome P450 enzymes), increase lipophilicity for membrane permeation, and tune pharmacological activity. Approximately 20% of pharmaceuticals contain at least one C-F bond.